有乳腺癌或卵巢癌病史女性基因检测率的全国估计
该研究利用美国全国健康访谈调查三个癌症控制模块(2005、2010、2015年)的汇总横断面数据,评估有乳腺癌或卵巢癌病史且符合部分2017年NCCN标准的成年女性的基因检测情况。
要点
- 符合部分2017年NCCN标准的乳腺癌病史女性中,15.3%接受了基因检测。
- 卵巢癌病史女性中10.5%接受了基因检测,13.1%被建议检测。
核心结论
- 有乳腺癌或卵巢癌病史且符合部分国家综合癌症网络标准的个体中,不足五分之一接受了基因检测,多数从未与医疗人员讨论过检测,需要大规模全国性努力来解决这一未满足需求。
研究设计与样本
- 研究采用美国全国健康访谈调查三个癌症控制模块(2005年、2010年、2015年)的汇总横断面数据,该调查为全国性面对面家庭访谈调查。
- 纳入对象为有乳腺癌和/或卵巢癌病史的成年女性,且符合基于诊断年龄和家族史的特定2017年美国国家综合癌症网络资格标准。
- 共纳入47,218名女性,其中2.7%有乳腺癌病史,0.4%有卵巢癌病史。
主要发现
- 乳腺癌病史者中35.6%符合一项或多项特定资格标准;其中29.0%讨论过检测,20.2%被建议接受检测,15.3%接受了检测。
- 各资格标准的检测率从6.2%(有卵巢癌亲属)到18.2%(诊断年龄≤45岁)不等。
- 卵巢癌病史者中15.1%讨论过检测,13.1%被建议接受检测,10.5%接受了检测。
关键数值与推荐
- 乳腺癌病史者符合特定2017年美国国家综合癌症网络资格标准的比例为35.6%。
- 乳腺癌病史者中各资格标准的检测率范围为6.2%(有卵巢癌亲属)至18.2%(诊断年龄≤45岁)。
- 卵巢癌病史者中讨论检测、被建议检测和接受检测的比例分别为15.1%、13.1%和10.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose In the United States, 3.8 million women have a history of breast (BC) or ovarian cancer (OC). Up to 15% of cases are attributable to heritable mutations, which, if identified, provide critical knowledge for treatment and preventive care. It is unknown how many patients who are at high risk for these mutations have not been tested and how rates vary by risk criteria. Methods We used pooled cross-sectional data from three Cancer Control Modules (2005, 2010, 2015) of the National Health Interview Survey, a national in-person household interview survey. Eligible patients were adult females with a history of BC and/or OC meeting select 2017 National Comprehensive Cancer Network eligibility criteria on the basis of age of diagnosis and family history. Outcomes included the proportion of individuals reporting a history of discussing genetic testing with a health professional, being advised to undergo genetic testing, or undergoing genetic testing for BC or OC. Results Of 47,218 women, 2.7% had a BC history and 0.4% had an OC history. For BC, 35.6% met one or more select eligibility criteria; of those, 29.0% discussed, 20.2% were advised to undergo, and 15.3% underwent genetic testing. Testing rates for individual eligibility criteria ranged from 6.2% (relative with OC) to 18.2% (diagnosis ≤ 45 years of age). For OC, 15.1% discussed, 13.1% were advised to undergo, and 10.5% underwent testing. Using only four BC eligibility criteria and all patients with OC, an estimated 1.2 to 1.3 million individuals failed to receive testing. Conclusion Fewer than one in five individuals with a history of BC or OC meeting select National Cancer Comprehensive Network criteria have undergone genetic testing. Most have never discussed testing with a health care provider. Large national efforts are warranted to address this unmet need.
引用
- Childers CP, Childers KK, Maggard-Gibbons M, et al. National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. J Clin Oncol. 2017. PMID: 28820644. doi:10.1200/JCO.2017.73.6314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。